Selected Publications

Fathi AT, Perl AE, Fell GG, Jonas BA, Ragon BK, Mims AS, Borate U, Mannis GN, Quillen K, Stahl M, Aubrey BJ, Koller P, Artz AS, Al Malki MM, Stein AS, Marcucci G, Peters MLB, Graubert TA, Westervelt P, Amrein PC, Hock HR, Brunner AM, Hobbs G, Narayan R, Lee MH, Miller PG, Watson AL, Hao R, Marola AC, Lombardi-Story J, Dhaver S, Grunwald MR, Chen YB, Weinstock MJ, Matthews AH, McGovern I, Wood BL, Hourigan CS, Neuberg DS, El-Jawahri A, Aldoss I.: Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia. N Engl J Med 395: 845-858, Sep 2026.

Ambinder A, Levis M, Wang X, Pratz K, Matthews A.: A real-world analysis of the impact of azole antifungal prophylaxis on outcomes in patients with newly diagnosed acute myeloid leukemia treated with venetoclax-based therapy. Leuk Res 164, Mar 2026.

Skuli SJ, Bakayoko A, Kruidenier M, Manning B, Pammer P, Salimov A, Riley O, Brake-Sillá G, Dopkin D, Bowman M, Martinez-Gutierrez LN, Anderson CC, Reisz JA, Buono R, Paul M, Saland E, Liccardo F, DeVine A, Wong S, Xu JP, Nee E, Hausler R, Boettcher S, Sebti SM, Lai C, Maxwell KN, Sarry JE, Fruman DA, D'Alessandro A, Mesaros C, Keith B, Simon MC, Sung PJ, Wertheim G, Skuli N, Bowman RL, Matthews A, Carroll M.: Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response. Leukemia Jul 2025.

Wang X, Gimotty PA, Matthews AH, Mamtani R, Luger SM, Hexner EO, Babushok DV, McCurdy SR, Frey NV, Bruno XJ, Gill S, Martin ME, Paralkar VR, Maillard I, Porter DL, Loren AW, Perl AE, Pratz KW, Getz KD, Lai C.: Evolving racial/ethnic disparities in AML survival in the novel therapy era. Blood Adv 9(3): 533-544, Feb 2025.

Rowe M, Babushok D, Carroll M, Carulli A, Frey N, Gill S, Hexner E, Hirsh R, Hossain N, Lai C, Loren A, Luger S, Maillard I, McCurdy S, Matthews A, Martin ME, Paralkar VR, Perl A, Porter D, Pratz K, Stadtmauer E, Bruno XJ.: Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen. Eur J Haematol 114(4): 626-635, Dec 2024.

Takeshi Onoue, Andrew H Matthews, Azin Vakilpour, Yu Kang, Bénédicte Lefebvre, Amanda M Smith, Shannon R McCurdy, Michael G Fradley, Joseph Carver, Jesse Chittams, Marielle Scherrer-Crosbie: Cardiotoxicity of venetoclax in patients with acute myeloid leukemia: comparison with anthracyclines. Cardio-Oncology 10(1), Nov 2024 Notes: DOI: 10.1186/s40959-024-00275-5.

Matthew P Connor, Neeharika Prathapa, Noelle V Frey, Saar I Gill, Elizabeth O Hexner, Ximena Jordan Bruno, Catherine E Lai, Alison W Loren, Selina M Luger, Andrew H Matthews, Shannon R McCurdy, Alexander E Perl, David L Porter, Arlene Zeringue, Joseph H Oved, Timothy S Olson, Keith W Pratz, Daria V Babushok: Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia. Haematologica 8(109): 2732-2737, Aug 2024.

Laczko D, Poveda-Rogers C, Matthews AH, Snaith O, Luger S, Bagg A, Caponetti GC, Morrissette JJD, Yang G.: RAD21 mutations in acute myeloid leukemia. Leuk & Lymphoma 65(7): 958-964, Jul 2024.

Matthews A, Fenu E, Skuli SJ, Harris JC, Lai C.: Immunohistochemistry-based detection of TP53 mutations in acute myeloid leukemia: a promising high sensitivity diagnostic approach. Leuk & Lymphoma 65(7): 1012-1015, Jul 2024.

Rowe M, Babushok D, Carroll M, Carulli A, Frey N, Gill S, Hexner E, Hirsh R, Hossain N, Lai C, Loren A, Luger S, Maillard I, McCurdy S, Matthews A, Martin ME, Paralkar VR, Perl A, Porter D, Pratz K, Stadtmauer E, Bruno XJ.: Tumor Lysis Syndrome in Acute Myeloid Leukemia Patients Treated With a Venetoclax Based Regimen. Eur J Haematol 114(4): 626-635, Apr 2024.